Koers C21 Investments Inc Toronto S.E.
Aandelen
CWQ
CA23129E2069
Farmaceutische producten
Omzet 2022 | 32,98 45,09 30,72 | Omzet 2023 | 28,89 39,5 26,9 | Marktkapitalisatie | 30,67 mln. 41,93 mln. 28,56 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | 10 mln. 13,67 mln. 9,31 mln. | Nettowinst (verlies) 2023 | - 0 0 | EV/omzet 2022 | 2.159.079 x |
Nettoschuld 2022 | 16,47 mln. 22,52 mln. 15,34 mln. | Nettoschuld 2023 | 10,24 mln. 14,01 mln. 9,54 mln. | EV/omzet 2023 | 1.416.161 x |
K/w-verhouding 2022 |
4,98
x | K/w-verhouding 2023 |
223
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 81,24% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Sonny Newman
CEO | Chief Executive Officer | - | 08-07-19 |
Michael Kidd
DFI | Director of Finance/CFO | - | 26-07-18 |
Aron Swan
COO | Chief Operating Officer | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Donald Macdonald
CHM | Chairman | - | 18-06-18 |
Leonard Werden
BRD | Director/Board Member | - | 25-07-17 |
Michael Kidd
DFI | Director of Finance/CFO | - | 26-07-18 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+26,93% | 5,55 mld. | |
-33,55% | 3,52 mld. | |
-3,74% | 3,03 mld. | |
-26,09% | 2,59 mld. | |
-10,93% | 2,28 mld. | |
+41,50% | 1,88 mld. | |
+41,84% | 1,46 mld. | |
-12,94% | 1,43 mld. | |
+47,62% | 1,42 mld. |